Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism
- 1 December 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 27 (6) , 623-629
Abstract
Purpose of review Better tools are sorely needed for both the prevention and treatment of cardiovascular diseases, which account for more than one-third of the deaths in Western countries. MicroRNAs typically regulate the expression of several mRNAs involved in the same biological process. Therapeutic manipulation of miRNAs could restore the expression of multiple players within the same physiologic pathway, and ideally offer better curative outcomes than conventional approaches that target only one single player within the pathway. This review summarizes available studies on the prospective value of targeting miRNAs to prevent dyslipidemia and atherogenesis. Recent findings Silencing the expression of miRNAs that target key genes involved in lipoprotein metabolism in vivo with antisense oligonucleotides results in the expected de-repression of target mRNAs in liver and atherosclerotic plaques. However, the consequences of long-term antimiRNA treatment on both circulating lipoproteins and athero-protection are yet to be established. Summary A number of studies have demonstrated the efficacy of miRNA mimics and inhibitors as novel therapeutic tools for treating dyslipidemia and cardiovascular diseases. Nevertheless, concerns over unanticipated side-effects related to de-repression of additional targets should not be overlooked for miRNA-based therapies.Keywords
This publication has 54 references indexed in Scilit:
- MicroRNAs 185, 96, and 223 Repress Selective High-Density Lipoprotein Cholesterol Uptake through Posttranscriptional InhibitionMolecular and Cellular Biology, 2013
- miR‐33 controls the expression of biliary transporters, and mediates statin‐ and diet‐induced hepatotoxicityEMBO Molecular Medicine, 2012
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingProceedings of the National Academy of Sciences, 2011
- Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*Journal of Biological Chemistry, 2010
- MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 ( Srebp2 ) regulates HDL in vivoProceedings of the National Academy of Sciences, 2010
- miR-33 links SREBP-2 induction to repression of sterol transportersProceedings of the National Academy of Sciences, 2010
- MiR-33 Contributes to the Regulation of Cholesterol HomeostasisScience, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005